Navigation Links
Eamonn Hobbs Joins the Board of Directors at Cappella
Date:2/17/2010

GALWAY, Ireland, February 17, 2010 /PRNewswire/ -- Cappella (http://www.cappella-med.com/), Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board of Directors ( http://www.cappella-med.eu/index.php?option=com_content&view=article&id=181:bf-directors&catid=4). According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and Managing Partner at PolyTechnos Venture-Partners GmbH, "Eamonn's wealth of expertise and solid track record of success in our medical device field makes him a formidable source of wisdom and judgement for the road ahead of Cappella. The company's commercial programs and global market expansion will greatly benefit from Mr Hobbs' insights."

Mr. Eamonn Hobbs, President, CEO, & Director of Delcath Systems, Inc. is an entrepreneurial senior executive with over 25 years of medical device experience and demonstrated success in profitable business creation, general management, sales and marketing and product development. When asked to comment on his recent appointment, Mr. Hobbs stated, "I am delighted to join Cappella's Board of Directors and support the cause of this company which is all about addressing a substantial unmet medical need. Whereas long under-diagnosed and under-served, bifurcational lesions have now attracted the much deserved attention of the medical community and I am convinced that Cappella has put the best team on the field to tackle the challenge. I am thrilled to work with Dr. Art Rosenthal and our Board of Directors to deliver this technology to patients in need."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard(R) (http://www.cappella-med.eu/index.php?option=com_content&view=article&id=1&Itronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, see: http://www.cappella-med.com.

(Due to the length of some of the URLs in this release, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

Links: Cappella : http://www.cappella-med.com/

SOURCE Cappella Inc.


'/>"/>
SOURCE Cappella Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
2. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
3. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
4. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
5. CooperVision Adds Global Professional Relations Role; Richard Clompus Joins Company as Vice President
6. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
7. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
8. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
9. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
10. PFC Pharma Joins DATATRAKs CRO Connect Program
11. William Cork Joins Fenwal as Chief Technology Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):